相关实验视频

Updated: Jul 1, 2025

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

适应性多干预试验平台,以改善纤维化间歇性肺部疾病患者的护理

Leticia Kawano-Dourado^1,2,3, Tejaswini Kulkarni⁴, Christopher J Ryerson⁵

¹Hcor Research Institute, Hcor Hospital, Sao Paulo, Brazil ldourado@hcor.com.br.

|March 6, 2024

概括

这项研究介绍了REMAP-ILD,这是一种新型的适应性平台,可以加速治疗纤维化间歇性肺部疾病 (fILD) 的药物开发. 这种方法旨在通过克服传统临床试验的局限性来改善患者护理.

科学领域:

肺部病理学肺部病理学
临床试验设计临床试验设计
药物开发药物开发

背景情况:

纤维化间歇性肺部疾病 (fILDs) 具有显著的发病率和死亡率.
目前对fILDs的治疗方法有限,只有两种已批准的疗法可以减缓纤维化进展.
迫切需要加快用于filds的药物开发,因为管道很长.

研究的目的:

引入一个创新的研究方法的概念和设计,用于药物开发在fILD.
描述REMAP-ILD (在fILD中的随机嵌入式多因素适应性平台) 平台.
概述REMAP-ILD的潜力,以加快提供有效治疗的速度.

主要方法:

雷马普-ILD平台采用多因素,适应性设计.
它结合了响应性自适应随机化和成功和徒劳的预规定的门.
该平台针对患有fILD的成年患者,重点关注使用强迫生命能力和死亡率的疾病进展模型.

主要成果:

主要结局指标是12个月的疾病进展模型.
干预措施的有效性和安全性将使用适应性随机化进行评估.
在REMAP-ILD中,优先考虑多样性,公平,包容性以及对数据共享的开放科学方法.

结论:

REMAP-ILD提供了一个创新的,高效的适应性平台,以加快对fILD患者的护理.
全球合作,新的分析方法和实用性试验交付是关键组成部分.
这种方法旨在克服传统的野外随机对照试验的局限性.

关键词:

结合性组织疾病与肺部疾病相关.过敏性肺炎是一种过敏性肺炎.异形性肺纤维化症异形性肺纤维化症间歇性纤维化间歇性纤维化类风湿性肺部疾病类风湿性肺部疾病

更多相关视频

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Published on: July 19, 2024

相关概念视频

Flail Chest-II

Flail Chest-II

Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...